Showing 1 - 2 results of 2 for search 'Fadi G. Haddad', query time: 0.01s Refine Results
  1. 1
    Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab

    Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab by Nicholas J. Short, Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, Omer Karrar, Sanam Loghavi, Lewis Nasr, Fadi G. Haddad, Jayastu Senapati, Rebecca Garris, Koichi Takahashi, Elias Jabbour

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia

    Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell... by Roberta S. Azevedo, Wei-Ying Jen, Danielle Hammond, Fadi G. Haddad, Alexis Geppner, Ghayas C. Issa, Koji Sasaki, Jayastu Senapati, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Tapan M. Kadia

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: